View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 23, 2022

Ribon initiates Phase I trial of atopic dermatitis treatment

The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.

Ribon Therapeutics has commenced the healthy volunteer segment of its first-in-human Phase I clinical trial to analyse the potential of its oral therapy, RBN-3143, to treat atopic dermatitis.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

A poly (ADP-ribose) polymerase family member 14 (PARP14) inhibitor, RBN-3143 could be used to treat various inflammatory diseases.

Expressed in tissues of inflammatory diseases, PARP14 facilitates the inflammatory cells infiltration such as eosinophils and neutrophils, the decline of which could have advantages over existing treatments.

Selectively hindering PARP14 causes a decline in alarmins and IL-17 and IL-4/13 signalling pathway dampening. 

The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.

Ribon Therapeutics president and CEO Prakash Raman said: “The news of the initiation of RBN-3143, our second programme to move into the clinic, is an important advancement for Ribon that broadens our Company’s portfolio to now include first-in-class programmes in both oncology and inflammatory diseases, leveraging our pioneering research in the role of NAD+-utilising enzymes in stress support pathways. 

“As a first-in-class, oral small molecule inhibitor of PARP14, RBN-3143 has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.”

Apart from RBN-3143, the portfolio of the company comprises another first-in-class clinical programme, RBN-2397, targeting various indications in oncology and inflammatory diseases.

In July last year, Ribon raised $65m in a funding round led by Deerfield Management and US Venture Partners.

New investors Avego BioScience Capital, GV, Monashee Investment Management and Peregrine Ventures also took part in the financing round.

The funds were used to advance the clinical development of its precision treatment candidates.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU